Andrew Rodican, PA
Medical · North Haven, CTNPI 1922098383
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 340 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AbbVie at 37.6% of the total. Reporting peaked in 2024 at $1,925 and has fallen 98.8% since, to $24 in 2025. Among medical clinicians in CT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 340 payments — averaging $14.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$790
- AstraZeneca$631
- GSK$256
- Lilly USA, LLC$215
- Indivior Inc.$182
- plus $997 from 17 others
What the payments were for
- Food & beverage$4,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 155 | $1,850 |
| Novo Nordisk | 77 | $790 |
| AstraZeneca | 30 | $631 |
| GSK | 13 | $256 |
| Lilly USA, LLC | 11 | $215 |
| Indivior Inc. | 7 | $182 |
| Astellas Pharma US Inc | 5 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| Pfizer | 6 | $118 |
| Amgen | 6 | $109 |
| Alkermes, Inc. | 5 | $98 |
| Braeburn Inc. | 3 | $63 |
| Corium, LLC | 3 | $61 |
| Merck | 2 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Corcept Therapeutics | 1 | $29 |
| Boehringer Ingelheim | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,921 in reported general payments places this provider in the 90th percentile of 592 medical providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 139 | $144,244 |
| OxycontinOxycodone Hcl | 12 | $67,753 |
| FarxigaDapagliflozin Propanediol | 32 | $38,159 |
| MounjaroTirzepatide | 34 | $37,198 |
| JardianceEmpagliflozin | 19 | $34,500 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $27,466 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 40 | $25,295 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 120 | $24,022 |
| JanuviaSitagliptin Phosphate | 21 | $21,973 |
| EliquisApixaban | 20 | $17,031 |
| XareltoRivaroxaban | 12 | $15,941 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $15,913 |
| TradjentaLinagliptin | 15 | $11,194 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $8,868 |
| MovantikNaloxegol Oxalate | 15 | $8,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $790 | $144,244139 claims |
| MerckJanumet, Januvia | $46 | $49,43937 claims |
| Boehringer IngelheimJardiance, Tradjenta | $26 | $45,69434 claims |
| AstraZenecaFarxiga | $631 | $38,15932 claims |
| Lilly USA, LLCMounjaro | $215 | $37,19834 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $256 | $28,86849 claims |
| Indivior Inc.Suboxone | $182 | $25,29540 claims |
| PfizerEliquis | $118 | $17,03120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 592 medical providers in Connecticut.
Other medical in North Haven
- Rebecca GrilloNorth Haven$7K
- Shilpa DesaiStamford$215K
- Gregory RauNew Haven$211K
- John JasinskiNorwalk$185K
- Brianna PaesanoStamford$153K
- Debra SullivanDerby$100K
- Ryan DonovanNew Haven$75K
- Jonica PagnuccoWaterbury$32K
- Alyssa GreenleafSouthington$26K
- Mark VolpeSuffield$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.